This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (48)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Behavioral Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Quality of Life  • Randomized Controlled Trial  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Relationship to Patient-Reported Quality of Life

Deborah M. Miller, PhD; Richard A. Rudick, MD; Gary Cutter, PhD; Monika Baier, MS; Jill S. Fischer, PhD

Arch Neurol. 2000;57:1319-1324.

Background  The Multiple Sclerosis Functional Composite (MSFC) was recommended by a task force of the National Multiple Sclerosis Society as a new clinical outcome measure for clinical trials. The task force recommended that the MSFC be validated against other measures of the disease, such as patient-reported quality of life.

Methods  Three hundred patients with multiple sclerosis (MS) representing the spectrum of disease severity were included in this cross-sectional study. The MSFC and Kurtzke Expanded Disability Status Scale (EDSS) were used as measures of disease severity. Clinical relevance of the disease severity scores was analyzed using measures included in the Multiple Sclerosis Quality of Life Inventory. The MSFC and EDSS scores were correlated with self-reported employment status, the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), and the Sickness Impact Profile (SIP).

Results  The MSFC and EDSS scores were strongly correlated (r = -0.80, P<.001). The MSFC scores were correlated with patient-reported physical functioning (SIP Physical Summary Scale: r = -0.71, P<.001; SF-36 Physical Component Score: r = -0.41, P<.001). The MSFC scores were significantly but more weakly correlated with emotional functioning (SIP Psychosocial Summary Scale: r = -0.34, P<.001). After controlling for EDSS scores, there were significant residual correlations between the MSFC scores and measures of health-related quality of life, suggesting that the MSFC accounts for the variability in health-related quality of life measures not reflected by the EDSS.

Conclusions  The observed strong correlations between MSFC scores and validated measures of self-reported quality of life indicate that the MSFC scores are clinically relevant. This study supports a recommendation by the National Multiple Sclerosis Society Task Force to use the MSFC as a clinical outcome measure.

From the Mellen Center, Cleveland Clinic Foundation, Cleveland, Ohio (Drs Miller, Rudick, and Fischer); and AMC Cancer Research Center, Denver, Colo (Dr Cutter and Ms Baier).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(9):1387-1388.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Introduction to Best practice recommendations for the selection and management of patients with MS on natalizumab
Munschauer et al.
Mult Scler 2009;15:S1-S6.
 

Grip Force Control in Individuals With Multiple Sclerosis
Iyengar et al.
Neurorehabil Neural Repair 2009;23:855-861.
ABSTRACT  

Assessing disability progression with the Multiple Sclerosis Functional Composite
Rudick et al.
Mult Scler 2009;15:984-997.
ABSTRACT  

Optimal reference population for the multiple sclerosis functional composite
Fox et al.
Mult Scler 2007;13:909-914.
ABSTRACT  

The usefulness of evaluative outcome measures in patients with multiple sclerosis
de Groot et al.
Brain 2006;129:2648-2659.
ABSTRACT | FULL TEXT  

Memory performance in multiple sclerosis patients correlates with central brain atrophy
Hildebrandt et al.
Mult Scler 2006;12:428-436.
ABSTRACT  

The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis
Nieuwenhuis et al.
Mult Scler 2006;12:495-500.
ABSTRACT  

Review Paper: Measuring outcomes for neurological disorders: a review of disease-specific health status instruments for three degenerative neurological conditions
Heffernan and Jenkinson
Chronic Illness 2005;1:131-142.
ABSTRACT  

Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review
Gruenewald et al.
Mult Scler 2004;10:690-725.
ABSTRACT  

Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional C omposite
Hobart et al.
Mult Scler 2004;10:41-46.
ABSTRACT  

The patient's perception of a (reliable) change in the Multiple Sclerosis Functional C omposite
Hoogervorst et al.
Mult Scler 2004;10:55-60.
ABSTRACT  

Validity and reliability of the MSQ LI in cognitively impaired patients with multiple sclerosis
Marrie et al.
Mult Scler 2003;9:621-626.
ABSTRACT  

A nxiety and depression influence the relation between disability status and quality of life in multiple sclerosis
Janssens et al.
Mult Scler 2003;9:397-403.
ABSTRACT  

Factors that predict Health-Related Q uality of Life in patients with relapsing -remitting multiple sclerosis
Miller et al.
Mult Scler 2003;9:1-5.
ABSTRACT  

The use of quality of life measures in multiple sclerosis research
Nortvedt and Riise
Mult Scler 2003;9:63-72.
ABSTRACT  

Developing clinical outcome measures in multiple sclerosis: an evolving process
Thompson
Mult Scler 2002;8:357-358.
 

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials
Rudick et al.
Mult Scler 2002;8:359-365.
ABSTRACT  

Benefit of interferon {beta}-1a on MSFC progression in secondary progressive MS
Cohen et al.
Neurology 2002;59:679-687.
ABSTRACT | FULL TEXT  

Frontiers in Neuropharmacotherapy Part II: Multiple Sclerosis and Parkinson's Disease
Chappell and Cohen
Journal of Pharmacy Practice 2002;15:221-240.
ABSTRACT  

Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial
Cohen et al.
Arch Neurol 2001;58:961-967.
ABSTRACT | FULL TEXT  

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
Rudick et al.
Neurology 2001;56:1324-1330.
ABSTRACT | FULL TEXT  

Quality of life as a predictor for change in disability in MS
Haupts et al.
Neurology 2001;56:1250-1250.
FULL TEXT